Data-Driven Insights
Posts for tag: Orphan Drugs
September 26, 2018 | Brandon Underwood
The 340B program is subject to increasing scrutiny as pharmaceutical manufacturers search for solutions to identify and act on non-compliance such as diversion and duplicate discounts. This post is taken from the Q&A session of IntegriChain's recent 340B webinar. Topics discussed include growth in contract pharmacies/covered entities, 340B discount pricing for orphan drugs, and validation of 340B entities.
July 27, 2018 | David Carlson
Rare diseases affect 30 million people in the United States, which roughly equates to 10% of the population. In 2017, 40% of the novel drugs approved by the FDA were designated to treat a rare disease. As approvals for rare disease treatments increase, these products account for an ever increasing share of overall pharmaceutical sales. The Payer community is reaching for value as per patient costs rise. This post discusses value-based contracts as a mutually beneficial solution for Payers and pharmaceutical manufacturers and the meaningful role analytics can play in executing and managing these innovative agreements.